###### Key questions

What is already known about this subject?
=========================================

-   No-reflow (NR) phenomenon is associated with poor clinical outcomes, and a number of independent predictors have been identified. Risk scores developed from these variables are of limited clinical use due to requirement of data not routinely available at the time of primary percutaneous coronary intervention.

What does this study add?
=========================

-   Of patients with ST-elevation myocardial infarction (STEMI) in a contemporary UK population, 13.9% suffered from NR, and these patients demonstrated a sevenfold increased rate of in-hospital death. Independent predictors of NR quantifiable prior to coronary intervention were increased lesion complexity, admission systolic hypertension, weight of \<78 kg and history of hypertension. These variables, within a statistical model, developed a risk score deemed to be a good test for predicting NR.

How might this impact on clinical practice?
===========================================

-   The risk score, following further validation, would have a role in prediction of high-risk patients, guiding management strategy aiming to prevent NR and to improve outcomes.

-   The score could further have use as a research tool, identifying a high-risk population for exploration of interventions on NR, as randomisation of an unselected STEMI cohort has established minimal clinical impact on NR from current therapies.

Introduction {#s1}
============

Urgent reperfusion has been the gold standard of care for ST-elevation myocardial infarction (STEMI) since the 1980s when thrombolysis was proven to significantly reduce all-cause mortality.[@R1] In the 1990s, this was challenged with superior outcomes in those managed with primary percutaneous coronary intervention (PPCI).[@R2] However, not all patients treated with PPCI have successful reperfusion. In 1992, Ito *et al*[@R3] first described the phenomenon of 'no reflow' (NR) in humans with acute myocardial infarction, whereby perfusion is not re-established despite patency of the epicardial coronary artery. The incidence of NR quoted in the literature is highly variable, ranging from 5% to 65%.[@R4] However, all studies have consistently demonstrated that NR has a negative impact on prognosis with larger infarct size, increased frequency of left ventricular (LV) dysfunction, cardiogenic shock, stroke and predisposition to arrhythmia.[@R7]

Given the importance of NR, a number of studies and registries have aimed to identify those at greatest risk,[@R7] and non-validated risk scores have been developed.[@R10] However, these scores are not clinically useful as they incorporate variables such as neutrophil/lymphocyte count, not commonly available at the time of intervention. There is a need for interventionists to be able to identify high-risk patients prior to PPCI, to enable a more aggressive pharmacotherapy regime[@R12] and modification of the percutaneous coronary intervention (PCI) strategy[@R13] in order to reduce the risk of NR. The aims of this study therefore were to evaluate the incidence of NR in consecutive patients with STEMI treated with contemporary PPCI and to identify the independent predictors of NR in order to develop a clinically usable risk score.

Methods {#s2}
=======

This was an open single UK centre prospective case--control study. Hull University Teaching Hospitals NHS Trust provides a 24/7 tertiary PPCI service to a population of 1.2 million. The overall cohort was defined as consecutive patients presenting with STEMI treated with PPCI. Cases were subjects who suffered NR at any stage of the procedure, and the control comparators were those who did not have evidence of NR. Clinical outcomes were documented in-hospital and at 30 days.

NR phenomenon was defined as[@R5]

-   Angiographical evidence of reopening of the occluded coronary artery with no evidence of flow-limiting residual stenosis (\<50%), dissection, vessel spasm or thrombus burden.

-   Angiographical documentation of thrombolysis in myocardial infarction (TIMI) flow grade ≤II.

-   A TIMI flow grade III with a myocardial blush grade 0 or I, at least 10 min after the end of the PPCI procedure.

The main inclusion criteria were patients ≥18 years old presenting with STEMI (as defined in [online supplementary material](#SP1){ref-type="supplementary-material"}) appropriate for PPCI over a 6-month period between December 2015 and May 2016. If coronary intervention was not procedurally possible (eg, unable to wire the vessel) or the patient did not survive the index procedure, the subject was excluded. All patients were managed by the operators as clinically appropriate to optimise the final result.
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When a participant could not be contacted at follow-up (n=3), outcomes were available from the Myocardial Ischaemia National Audit Project database. Information was collected prospectively or from electronic records regarding patient demographics and baseline clinical characteristics, admission and procedural data, coronary angiographical findings and in-hospital investigations. Clinical outcomes in-hospital and at 30 days were recorded following patient contact. Major adverse cardiovascular event (MACE) was defined as the composite of cardiovascular death, myocardial infarction and stroke. Angiographical and echocardiography assessments were analysed offline by two investigators independently (JAR and ES). Quantitative coronary angiography (QCA) guidance/scale definitions were used to maximise consistency. Any discrepancies were further reviewed, and consensus was reached.

Continuous characteristics were expressed as mean and SD, and categorical data were expressed as numbers (percentages). Continuous data were analysed using one-way analysis of variance, and categorical characteristics were analysed with χ^2^ to assess for correlation with NR. Simple binary logistic regression models were used to observe any association between the correlated baseline clinical and angiographical factors with NR (reported as OR with 95% CI). Multiple backward stepwise logistic regression methodology enabled identification of independent variables in the prediction of NR. Receiver operating characteristic (ROC) curve analysis allowed conversion of continuous variables into dichotomous data with optimised cut-offs identified. The final categorical model was assessed with multiple logistic regression, and a score was calculated based on the β coefficient. Two-sided p values of \<0.05 were considered to indicate statistical significance, yet p\<0.1 was felt to require further assessment in the regression model. All analyses were undertaken on SPSS V.24.

The study was monitored in accordance with Hull and East Yorkshire Hospitals NHS Trust R&D department's standard operating procedures to ensure compliance with International Conference for Harmonisation of Good Clinical Practice and the Research Governance Framework 2005. There was no public or patient involvement in the conduct of this study. Data were collected and retained in accordance with the Data Protection Act 1998. Strengthening the Reporting of Observational Studies in Epidemiology statement guidelines were used in the reporting of this study.[@R14]

Results {#s3}
=======

The study enrolled 173 patients (68% male) with a mean age of 63 years (range 34--91 years). NR phenomenon was reported in 24 cases (13.9%) and occurred after predilation in 6 (25%), post-thrombectomy in 1 (4.2%), following stent implantation in 11 (45.8%) and after stent postdilation in 6 (25%).

The clinical characteristics of those developing NR were explored compared with the control group (those who did not develop NR) ([table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics and admission investigations of patients presenting with ST-elevation myocardial infarction comparing the NR group with the control group

                                          NR             P value                 
  --------------------------------------- -------------- ----------- ----------- -----------
  Age (years)                             62±13          70±13       **0.004**   
  Male                                    104 (70)       14 (58)     0.3         
  History                                                                        
   Diabetes mellitus                      21 (14)        3 (13)      0.8         
   Hypertension                           44 (30)        12 (50)     **0.047**   
   Hypercholesterolaemia                  35 (23)        6 (25)      0.9         
   Ischaemic heart disease                26 (17)        4 (17)      0.9         
   Smoking current                        62 (42)        5 (22)      **0.06**    
   Ex                                     46 (31)        8 (36)      0.6         
  Examination on admission                                                       
   Weight (kg)                            85±20          77±14       **0.087**   
   Heart rate (beats/min)                 75±19          78±20       0.5         
   Systolic blood pressure (mm Hg)        138±28         151±30      **0.03**    
   Diastolic blood pressure (mm Hg)       80±16          80±18       0.9         
   Blood glucose                          8.0±3.3        8.6±3.6     0.4         
  Killip class                                                                   
   I                                      118 (79)       15 (63)     **0.056**   
   II                                     25 (17)        7 (29)                  
   III                                    3 (2)          0 (0)                   
   IV                                     3 (2)          2 (8)                   
  Medication use prior to admission                                              
   Aspirin                                25 (17)        4 (17)      1.0         
   Dual antiplatelet therapy              2 (1)          0 (0)       0.6         
   Anticoagulation warfarin               7 (5)          1 (4)       0.9         
   DOAC                                   1 (1)          1 (4)       0.1         
   Statin                                 42 (28)        8 (33)      0.6         
  Time to treatment                                                              
   Symptoms to door time (min)            511±915        681±1185    0.4         
   Symptoms to balloon time (min)         543±918        720±1195    0.4         
   Door to balloon time (min)             32±14          39±41       0.1         
   Symptoms to aspirin time (min)         435±941        628±1268    0.4         
   Symptoms to P2Y~12~ antagonist (min)   510±923        656±1205    0.5         
  Inpatient investigations                Normal range                           
  Haemoglobin (g/L)                       (135--175)     142±18      135±16      **0.066**
  Neutrophil (×10^9^/L)                   (2.0--7.7)     11.1±11.5   11.5±4.1    0.8
  Platelet (×10^9^/L)                     (150--400)     248±95      216±73      0.1
  Creatinine (μmol/L)                     (50--120)      79±22       91±32       **0.038**
  eGFR (mL/min)                           (\>90)         89±26       78±32       **0.059**
  Albumin (g/L)                           (35--55)       36±5        34±4        **0.096**
  C reactive protein                      (\<10)         19±36       16±30       0.8
  NT-proBNP (pg/mL)                       (\<400)        1556±2499   3305±7708   **0.047**
  Resolution of ECG ST change             88 (64)        12 (57)     0.530       
  Left ventricular dysfunction                                                   
   None                                   62 (43)        7 (29)      0.5         
   Mild                                   46 (32)        8 (33)                  
   Moderate                               29 (20)        6 (25)                  
   Severe                                 9 (6)          3 (12.5)                

Continuous variables are expressed as mean±SD with correlation investigated with one-way analysis of variance. Categorical variables are expressed as number (percentage), with correlation investigated with χ^2^ test. P\<0.05 was deemed significant; however, p\<0.1 (bold) suggested further analysis was required.

DOAC, direct-acting oral anticoagulant; eGFR, estimated glomerular filtration rate; NR, no reflow; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

The former group was an older population with increased medical history of hypertension and presented with higher systolic blood pressures. Patients with NR had a delay across all recorded timings related to symptom onset and important clinical interventions, when compared with the patients who did not, though this failed to reach statistical significance.

Furthermore, [table 1](#T1){ref-type="table"} details the results of investigations obtained following the PPCI. Patients with NR had a higher creatinine level (p=0.038) and a trend to a lower haemoglobin level (p=0.066). The population with NR had a significantly greater level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) (p=0.047). In keeping with this, a numerical trend was evident for reduced LV function in the NR cohort; however, this did not reach statistical importance (p=0.502).

Analysis of the angiographical images demonstrated that the culprit vessel, location, length of the lesion or thrombus class did not influence the occurrence of NR ([table 2](#T2){ref-type="table"}). However, NR was related to increased lesion complexity (p=0.001). Baseline TIMI flow did not significantly differ between the cases and control patients; there was a highly significant reduction in final TIMI flow and myocardial blush grade (p\<0.001). Patients demonstrating reduced end TIMI flow/blush grade not categorised as NR pertain to cases failing to meet defining criteria, such as presence of distal emboli or dissection. NR cases with normal end procedure TIMI flow/blush grade represent patients who responded to procedural intervention administered during the PPCI.

###### 

Angiographical and procedural characteristics of patients presenting with ST-elevation myocardial infarction comparing the NR group with the control group

                                    NR          P value    
  --------------------------------- ----------- ---------- -------------
  Presence of multivessel disease   95 (64)     20 (83)    **0.059**
  Culprit vessel                                           
   LAD                              52 (35)     7 (29)     0.8
   RCA                              72 (48)     14 (58)    
   LCx                              15 (10)     2 (8)      
   Other                            10 (7)      1 (4)      
  Reference vessel diameter (mm)    3.0±0.6     3.0±0.5    1.0
  Lesion length (mm)                15.2±10.3   18.3±7.5   0.2
  Lesion complexity                                        
   A                                0           0          **0.001**
   B1                               48 (32)     1 (4)      
   B2                               85 (57)     15 (63)    
   C                                16 (11)     8 (33)     
  Thrombus class                                           
   0                                3 (2)       0          0.2
   1                                7 (5)       0          
   2                                2 (1)       1 (4)      
   3                                13 (9)      0          
   4                                17 (11)     3 (13)     
   5                                107 (72)    20 (83)    
  Initial TIMI flow                                        
   0                                105 (71)    20 (83)    0.4
   1                                16 (11)     1 (4)      
   2                                18 (12)     1 (4)      
   3                                10 (7)      2 (8)      
  Collaterals                                              
   No                               82 (55)     9 (38)     0.104
   Yes                              66 (45)     15 (62)    
  Final TIMI flow                                          
   0                                0           2 (8)      **\<0.001**
   1                                4 (3)       5 (21)     
   2                                11 (7)      15 (63)    
   3                                134 (90)    2 (8)      
  Final myocardial blush grade                             
   0                                3 (2)       8 (33)     **\<0.001**
   1                                5 (3)       7 (29)     
   2                                9 (6)       8 (33)     
   3                                128 (88)    1 (4)      

Continuous variables are expressed as mean±SD with correlation investigated with one-way analysis of variance. Categorical variables are expressed as number (percentage) with correlation investigated with χ^2^ test. P\<0.05 was deemed significant; however, p\<0.1 (bold) suggested further analysis was required.

LAD, left anterior descending; LCx, circumflex; NR, no reflow; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.

Patients with NR were more likely to be treated with predilation, and this was performed at higher inflation pressures than those without NR. There was a trend towards more stent postdilation. Patients with NR received a lower dose of unfractionated heparin; however, the activated clotting time results were not significantly different. Patients with NR were more likely to receive glycoprotein (GP) IIb/IIIa inhibitor therapy ([table 3](#T3){ref-type="table"}).

###### 

Procedural characteristics of patients presenting with ST-elevation myocardial infarction comparing those with no reflow to those without

                                                   No reflow   P value     
  ------------------------------------------------ ----------- ----------- -----------
  Heparin dose (units)                             8054±2347   6818±2260   **0.022**
   Activated clotting time (s)                     290±82      304±79      0.549
  Glycoprotein IIb/IIIa inhibitor use              33 (22)     6 (25)      0.784
  Predilation performed                            103 (70)    24 (100)    **0.002**
   Predilation balloon inflation pressure (atm)    12±3        14±4        **0.047**
   Predilation balloon diameter (mm)               2.5±0.5     2.5±0.4     0.848
  Stent inserted                                   140 (96)    24 (100)    0.312
   Stent inflation pressure (atm)                  15±2        15±3        0.988
   Stent diameter (mm)                             3.3±0.5     3.3±0.7     0.527
  Postdilation performed                           55 (38)     13 (54)     0.126
   Postdilation balloon inflation pressure (atm)   16±4        17±4        0.334
   Postdilation balloon maximal diameter (mm)      3.6±0.5     3.7±0.6     0.559
  Thrombectomy use                                 60 (41)     8 (33)      0.472
  Screening time                                   12.3±7.4    14.5±11.7   0.233
  Radiation exposure (DAP)                         5553±3427   5618±2940   0.930

Continuous variables are expressed as mean±SD with correlation investigated with one-way analysis of variance. Categorical variables are expressed as number (percentage) with correlation investigated with χ^2^ test. P\<0.05 was deemed significant; however, p\<0.1 (bold) suggested further analysis was required.

DAP, dose area product.

Clinical outcomes {#s3-1}
-----------------

The clinical outcomes are shown in [table 4](#T4){ref-type="table"}. Patients with NR had significantly worse outcome than those without NR. At 30 days, patients with NR had a higher rate of MACE (16.7% vs 5.4%; OR 3.5, 95% CI 1.0 to 12.9, p=0.05), driven by a significantly higher in-hospital mortality (12.5% vs 2.0%, p=0.009).

###### 

In-hospital and 30-day clinical outcomes

                             In-hospital   30 days                                   
  -------------------------- ------------- ---------- ------- ----------- ---------- -------
  Cardiovascular death       3 (2)         3 (12.5)   0.009   4 (2.7)     3 (12.5)   0.023
  Myocardial infarction      2 (1.3)       0          0.568   2 (1.3)     1 (4.2)    0.283
  Cerebrovascular accident   2 (1.4)       0          0.687   2 (1.4)     0          0.687
  MACE                       7 (4.7)       3 (12.5)   0.129   8 (5.4)     4 (16.7)   0.043
  Repeat revascularisation   4 (50)        0          0.220   0           0          
  Hospital readmission       --            --         --      17 (11.4)   3 (12.5)   0.754

Results quoted as number (percentage of relevant population), and correlation was investigated with χ^2^ test.

MACE, major adverse cardiovascular event.

Predictors of NO reflow {#s3-2}
-----------------------

All characteristics with NR correlation (p value\<0.1) underwent univariate analysis, and this determined increasing age, higher systolic blood pressure, lower heparin dose, prolongation of time between P2Y~12~ administration and arterial opening (balloon time), and angiographical classification of the lesion to be significant predictors of NR ([table 5](#T5){ref-type="table"}).

###### 

ORs for characteristics demonstrating correlation to no reflow

                                           OR     95% CI           P value
  ---------------------------------------- ------ ---------------- -----------
  Age                                      1.05   1.02 to 1.09     **0.005**
  Weight                                   0.97   0.95 to 1.0      **0.081**
  NT-proBNP                                1.00   1.0 to 1.0       0.103
  Haemoglobin                              0.98   0.95 to 1.0      **0.068**
  Albumin                                  0.93   0.85 to 1.01     0.1
  eGFR                                     0.98   0.97 to 1.0      **0.061**
  Heart failure (Killip class)             1.66   0.97 to 2.84     **0.066**
  Systolic blood pressure                  1.02   1 to 1.03        **0.03**
  Predilation balloon inflation pressure   1.17   1 to 1.62        **0.05**
  Aspirin to balloon time                  1.00   1 to 1.01        0.13
  P2Y~12~ antagonist to balloon time       1.01   1 to 1.01        **0.036**
  Smoker                                   0.38   0.13 to 1.08     **0.07**
  Hypertension                             2.39   1 to 5.72        **0.051**
  Intracoronary IIb/IIIa use               6.59   0.88 to 49.22    **0.066**
  Intravenous fluid use                    2.12   0.88 to 5.1      **0.095**
  Presence of multivessel disease          1.73   0.64 to 4.63     0.28
  Classification                                                   
   B2 versus B1                            8.47   1.09 to 66.13    **0.042**
   C versus B1                             24.0   2.78 to 206.96   **0.004**
   B2 versus C                             0.35   0.13 to 0.97     **0.043**

Figures show OR, 95% CI and subsequent p value. Killip class was entered as continuous variable. P\<0.05 was deemed significant; however, a p \<0.1 (bold) was considered for the prediction model.

eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

A prediction model was considered containing all variables deemed statistically important and could be quantified preintervention ([table 6](#T6){ref-type="table"}) (age, lesion classification, systolic blood pressure, hypertension and non-smoker). In addition, symptoms to PCI time and admission glucose were trialled in the model, as both had been judged important in established risk models,[@R10] yet neither strengthened the model. History of hypertension, lesion classification, systolic blood pressure on admission and patient weight were found to be the independent predictors of NR.

###### 

Important prediction variables divided into subcategories

  Precoronary intervention                Intraintervention /postintervention                        Secondary to NR?
  --------------------------------------- ---------------------------------------------------------- --------------------
  1\. Age.                                1\. Heparin dose.                                          
  2\. Lesion classification.              2\. Pre-dilation balloon inflation pressure.               
  3\. Systolic blood pressure.                                                                       
  4.P2Y~12~ antagonist to balloon time.   3.eGFR.![](openhrt-2019-001215ilf01.jpg){#img1}            1.eGFR.
  4\. Intracoronary IIb/IIIa.             2\. Intracoronary IIb/IIIa.                                
  5\. Hypertension.                                                                                  3\. Heart failure.
  6\. Non-smoker.                         5\. Haemoglobin.![](openhrt-2019-001215ilf02.jpg){#img2}   4\. Haemoglobin.
  7\. Weight.                             6\. Intravenous fluids Use.                                

Variables are divided into categories on whether information was available precoronary intervention or intraintervention/postintervention, or if data may be influenced by the presence of NR rather than contributing to risk of NR. The order represents the statistical weighting, with 1 associated with the most significant p value.

eGFR, estimated glomerular filtration rate; NR, no reflow.

Risk score {#s3-3}
----------

To enable risk score analysis, the continuous variables were transformed into binary outcomes. Systolic blood pressure of ≥138 mm Hg (area under the curve (AUC) 0.626; 95% CI 0.507 to 0.744, p=0.049) had a 66.7% sensitivity and 49.7% specificity for NR prediction. Weight of \<78 kg (AUC 0.618; 95% CI 0.490 to 0.746, p=0.088) conferred 55% sensitivity and 67.9% specificity for NR. Following reinterpretation of these measurements, the final model was found to be of good fit (Hosmer-Lemeshow 2.274, p=0.943) and a significant predictor of NR phenomenon (χ^2^ 28.6, p\<0.001). Approximately 31.3% variation in NR outcome can be explained by the grouping of the characteristics using Nagelkerke pseudo R^2^ value ([table 7](#T7){ref-type="table"}).

###### 

Preinterventional risk score

                            OR     95% CI         β coefficient   P value   Risk score
  ------------------------- ------ -------------- --------------- --------- ------------
  Lesion classification                           0.005                     
   B2                       10.5   1.3 to 88.8    2.35            0.03      2
   C                        37.7   3.9 to 369.2   3.63            0.002     3
  SBP≥138 mm Hg             4.2    1.3 to 13.8    1.43            0.019     1
  Weight\<78 kg             3.3    1.1 to 9.8     1.20            0.03      1
  History of hypertension   3.2    1.1 to 9.1     1.15            0.034     1

Exploration of categorical characteristics in a multiple logistic regression, entered in order or statistical importance. Risk score was calculate using the β coefficient ratio compared to the lowest value.

SBP, systolic blood pressure.

There was a significant difference between the risk score values of patients who suffered from NR (4.1±1) compared with those who did not (2.6±1) (p\<0.001), and the risk score was considered a good test (AUC 0.823; 95% CI 0.723 to 0.923, p\<0.001) ([figure 1](#F1){ref-type="fig"}). In depth review of the ROC curve stated a score of ≥3 had 90% sensitivity and 49.8% specificity (3/67, 7.1%; number of NR/total population (%)), compared with ≥4 with 75% sensitivity and 76.5% specificity (5/24, 17.2%) and ≥5 with 50% sensitivity and 94.1% specificity (10/18, 55%). Therefore, patients with a risk score of \<3 have a low risk, and those with a score of ≥5 have a high risk of developing NR.

![Receiver operating characteristic curve analysis for the no-reflow prediction model. ](openhrt-2019-001215f01){#F1}

Discussion {#s4}
==========

NR phenomenon occurred in 13.9% of a contemporary population of patients presenting with STEMI, which was lower than anticipated. This inconsistency is partly dependent on the definition of NR and the sensitivity of the defining methodology. In particular, angiographical evaluation is relatively insensitive as compared with imaging with cardiac MRI or myocardial contrast echocardiography.[@R16]

Although the incidence was lower, NR remains an important condition with a fourfold increase in MACE at 30 days. This is in keeping with previously published data,[@R4] and the impact is known to persist up to 5 years.[@R5] These data support the need for a predictive risk score.

Understanding the pathophysiology may give further explanations for this reduction in events. NR has a multifactorial aetiology and broadly can be defined by four distinct groups: (1) distal atherothrombotic embolisation, (2) ischaemic injury, (3) reperfusion injury, and (4) susceptibility of coronary microcirculation to injury. Distal embolisation is a result of debris (thrombi, endothelial cells and lipid matrix) migrating downstream from the primary lesion, leading to microvascular obstruction and further injury.[@R6] Ischaemic injury is relative to the duration of obstruction, secondary to the described thrombi, endothelial protrusions and extrinsic compression caused by oedematous change in the myocytes. Subsequently, platelets play a critical role in the development of the condition, and therapeutic practice switch in favour of newer P2Y~12~ inhibitors[@R18] could be contributory to the lower incidence, as ticagrelor/prasugrel are more potent antiplatelet agents compared with clopidogrel.[@R19] However, demonstration of NR reduction in randomised groups has not been seen. Our data also suggested a longer time elapse from symptoms to antiplatelet therapy in the NR group, although non-significant. Interestingly, a delay was seen across all timed variables for NR patents, implying prolonged obstruction/ischaemic injury. The findings in this cohort failed to reach statistical meaning, but larger studies support its importance.[@R7] Therefore, another plausible contributing factor is UK geography, with relative short distances to medical contact and final PPCI therapy compared with some of our international counterparts.

Our model found lesion severity quantified by B2/C classification had the highest predictive, value and its contribution to the risk score is a logical predictor. As described, the pathophysiology of NR is in part triggered by reperfusion injury secondary to inflammation and vasoconstriction induced by platelets, neutrophils and damaged endothelial cells,[@R6] a response directly proportional to lesion severity/length. Indeed, NR has been previously linked with lesion severity and the degree of disease burden.[@R7]

NR is primarily a disease of the endothelium and microvasculature, both of which are negatively impacted by the presence of long-term systemic hypertension.[@R23] Hence, hypertension results in a myocardial vasculature more susceptible to NR. It is conceivable that admission systolic hypertension is driven by either uncontrolled/undiagnosed hypertension, or systemic adrenergic stress response induced by the STEMI presentation. The former is important to acknowledge as hypertensive control can improve coronary microvascular function.[@R25] Myocardial ischaemia is known to stimulate catecholamine release and the renin--angiotensin system, resulting in systemic vasoconstriction proportional to the degree of ischaemia.[@R26] Mirroring this is the vasoconstriction seen in the coronary vessels during infarction,[@R27] and so systemic hypertension represents greater ischaemia and increased vasoconstriction, resulting in higher levels of ischaemic and perfusion injury contributing to NR.

Weight was also predictive with lower values representing an increase in risk. Patients with reduced body habitus may convey an older or potentially systemically unwell/frailer population. This is supported by the study demonstrating greater age, reduced estimated glomerular filtration rate and lower albumin levels in the NR cohort, although independently not predictive. Inversely, it may be more appropriate to consider increased weight being protective against NR. Although morbid obesity has been shown to convey a worse outcome for cardiovascular disease, overweight or obese states have been found to be protective.[@R28] Adipocytes are linked with anti-inflammatory cascades and reduction in oxidative stress,[@R29] which leads to consideration of 'healthy' overweight/obesity. Epicardial adipose tissue measurements, which has been shown to directly correlate to increased metabolic cardiovascular risk,[@R30] were similar in both our cohorts suggesting a 'healthier' obese state in the control population.

We carefully explored previously highlighted independent predictors in other risk models.[@R10] Age and time from symptoms to therapy was significantly different between groups but not independently predictive. Interestingly, marked hyperglycaemia was infrequently seen in our group (blood glucose≥12 mmol/L was 6.9%), which may relate to its failure to contribute to the model. Differences found may relate to the population/ethnicity or clinical practice differences or, in case of timings, the marked variation time to intervention demonstrated.

Conclusion {#s5}
==========

No reflow phenomenon is an important condition seen during PPCI for STEMI. It conveys an increased risk of MACEs. Independent predictors of NR available prior to coronary intervention were increased lesion complexity, systolic hypertension on admission, weight of \<78 kg and previous history of hypertension. Further international multicentre validation of this risk model is required.

Limitations {#s5-1}
-----------

The study was performed in a single UK centre with a small study population, which was almost solely Caucasian. This may limit its relevance to all populations. Furthermore, the diagnosis was angiography based rather than more sensitive methods, such as cardiac MRI or myocardial contrast echocardiography. However, this methodology was purposeful as it felt closer to real-world practice.
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